ldwide commercialization rights. The agreement also provides the company with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition. Eisai Co., Ltd. (Eisai) The company has a collaboration with Eisai to jointly develop and commercialize E2609 and BAN2401, two Eisai product candidates for the treatment of Alzheimer’s disease. Eisai serves as the global operational and regulatory lead for E2609 and BAN2401. Following marketing approval in major markets, the company would co-promote E2609 and BAN2401 with Eisai. In smaller markets, Eisai would distribute these products. The agreement also provides Eisai with options to jointly develop and commercialize two of the company’s candidates for Alzheimer’s disease, aducanumab and an anti-tau monoclonal antibody, upon the exchange or provision of clinical data. Upon exercise of the applicable option, the company would execute a separate collaboration agreement with Eisai on terms and conditions that mirror the financial arrangements that the company has with Eisai with respect to E2609 and BAN2401. Genentech (Roche Group) The company has a collaboration agreement with Genentech, which entitles the company to certain financial and other rights with respect to RITUXAN, GAZYVA and other anti-CD20 product candidates. Additionally, under the company’s agreement with Genentech, if ocrelizumab is approved, the company would receive tiered royalty payments on sales of ocrelizumab. Ionis The company has three separate exclusive, worldwide option and collaboration agreements with Ionis under which both companies would develop and commercialize antisense therapeutics for approximately three gene targets, Ionis’ product candidates for the treatment of myotonic dystrophy type 1, and the antisense investigational candidate, nusinersen for the treatment of SMA. The company also has a six-year research collaboration agreement with Ionis, under which both companies perform discovery level research and would develop and commercialize antisense and other therapeutics for the treatment of neurological disorders. Mitsubishi Tanabe Pharma Corporation (MTPC) In 2015, the company entered into an agreement with MTPC to license amiselimod, a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. Under the agreement, the company obtained worldwide rights to amiselimod, excluding Asia. The company is responsible for commercialization and is covering development costs outside of Asia. MTPC has the right to participate in the company’s global clinical trials and has an option to co-promote non-MS indications in the U.S. Samsung Bioepis The company and Samsung Biologics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. In 2013, the company entered into an agreement with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in specified E.U. countries, and in the case of BENEPALI, Japan. As of December 31, 2015, Samsung Bioepis' MAA for BENEPALI, an etanercept biosimilar referencing ENBREL, has been approved by the EC, and the MAA for FLIXABI, an infliximab biosimilars candidate referencing REMICADE, has been validated by the EMA. In addition to the company’s joint venture and commercialization agreement with Samsung Bioepis, the company licenses certain of its proprietary technology to Samsung Bioepis in connection with Samsung Bioepis's development, manufacture and commercialization of its biosimilar products. The company also provides technical development and technology transfer services to Samsung Bioepis, and manufactures clinical and commercial quantities of bulk drug substance of Samsung Bioepis' biosimilar products. Sangamo BioSciences, Inc. The company has an exclusive, worldwide research, development and commercialization collaboration and license agreement with Sangamo BioSciences, Inc. under which the companies would develop and commercialize product candidates using gene editing technologies for the treatment of two inherited b
biogen inc (IDP:Frankfurt)
225 Binney Street
Cambridge, MA 02142
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for IDP.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BIOGEN INC, please visit www.biogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.